{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie5f73o2w6cl44f5hbdcgfv7mwhfp5n6mnmid3caglvwieexn6qda",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm2pk6sooit2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreietmjb6suu5iybki3e5drcw7abhbkmqtzwszxblp6jssx4fvnn74e"
    },
    "mimeType": "image/jpeg",
    "size": 131264
  },
  "path": "/news/2026-05-crispr-approach-path-hepatitis-treatment.html",
  "publishedAt": "2026-05-17T10:30:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were able to specifically suppress the replication of the hepatitis E virus in human cells. Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. The team has now demonstrated that the virus can be targeted using an RNA-directed CRISPR system. The results, published on May 4, 2026, in the journal JHEP Reports, open new perspectives for the development of antiviral strategies.",
  "title": "New CRISPR approach may open path to hepatitis E treatment by blocking viral RNA"
}